ARRAY TECHNOLOGIES, INC. BOULDER, Colo., May 28, 2015 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on encorafenib, binimetinib and selumetinib (licensed to AstraZeneca) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 - June 2, 2015 in Chicago, Illinois. These three products are currently advancing in a total of 6 pivotal trials, with top-line results expected in 2015 from both the NEMO (binimetinib monotherapy in NRAS mutant melanoma patients) and SUMIT (selumetinib with dacarbazine in uveal melanoma patients) Phase 3 trials.
Ron Squarer, Chief Executive Officer of Array, noted, "We are encouraged to see eight ASCO abstracts reporting clinical results from Array-invented BRAF, MEK and HER2 drugs, while we await readouts later this year from two pivotal trials, NEMO and SUMIT."
The following is a summary of the presentations that will be given at ASCO:
ORAL PRESENTATIONS
Title: | A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment (Abstract #9007) |
Presenter: | Ryan J. Sullivan, MD |
Date: | Saturday, May 30, 3:27 - 3:39 p.m. CDT (Oral Presentation) |
Title: | A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST) (Abstract #10507) |
Presenter: | Ping Chi, MD, PhD |
Date: | Monday, June 1, 5:12 - 5:24 p.m. CDT (Oral Presentation) |
POSTER PRESENTATIONS
Title: | A phase Ib dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (Abstract #9051) |
Presenter: | Rachel N. Grisham, MD |
Date: | Saturday, May 30, 1:15 - 4:45 p.m. CDT |
Abstract #9051 will also be discussed at the Poster Discussion Session on Saturday, May 30, 4:45 - 6:00 p.m. | |
Title: | Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer (Abstract #2509) |
Presenter: | Geoffrey R. Oxnard, MD |
Date: | Saturday, May 30, 1:15 - 2:30 p.m. CDT |
Title: | A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib (V) in combination with the oral MEK inhibitor selumetinib (S) in solid tumors (Abstract #2583) |
Presenter: | Wasiru Olugbenga Saka |
Date: | Saturday, May 30, 1:15 - 2:30 p.m. CDT |
Title: | SWOG S1115: Randomized phase II trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer (Abstract #4119) |
Presenter: | Vincent M. Chung, MD |
Date: | Monday, June 1, 8 - 11:30 a.m. CDT |
Title: | A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197 (Abstract #8046) |
Presenter: | Garth Andrew Nicholas, MD |
Date: | Monday, June 1, 8 - 11:30 a.m. CDT |
Title: | ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets) (Abstract #612) |
Presenter: | Cristiano Ferrario, MD |
Date: | Saturday, May 30, 8 - 11:30 a.m. CDT |
Trials in Progress posters will also showcase the trial designs for the Phase 3 binimetinib trial in low-grade serous ovarian cancer (MILO), two filanesib Phase 2 trials in multiple myeloma (combination with carfilzomib, and single agent (AfFIRM), two ipatasertib (GDC-0068) Phase 2 trials in breast cancer (FAIRLANE and LOTUS) and the LOXO-101 Phase 1 trial in solid tumors.
All abstracts can be accessed through the ASCO website, http://abstract.asco.org/. After the presentations and posters are public, they will be available as PDFs on Array's website at www.arraybiopharma.com.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Six Phase 3 studies are currently advancing. These programs include three cancer drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (AstraZeneca). For more information on Array, please go to www.arraybiopharma.com.
CONTACT: | Tricia Haugeto |
(303) 386-1193 | |
thaugeto@arraybiopharma.com |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-announces-clinical-data-presentations-at-the-2015-asco-annual-meeting-300089644.html
SOURCE Array BioPharma Inc.
|
distributed by
|
